Adaptimmune Therapeutics plc Profit Margin

The latest profit margin for ADAPY is -260.82% as of June 2025. That compares with -51.44% in the prior-year period — down 407.1% year over year. That is below the Healthcare sector average of 10.58%. Investors often review this figure alongside Adaptimmune Therapeutics plc's historical trend and sector peers before judging valuation or financial health.

Over the past year, ADAPY's profit margin moved from -51.44% to -260.82% — a 407.1% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Adaptimmune Therapeutics plc's valuation or profitability profile.

Against Healthcare companies, ADAPY currently prints -260.82% for profit margin, while the sector average sits near 10.58%. That is roughly 2565.1% below the sector mean. Large gaps often invite a closer look at Adaptimmune Therapeutics plc's growth, margins, and balance sheet.

Profit Margin shows how effectively Adaptimmune Therapeutics plc converts resources into returns. At -260.82%, ADAPY may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -51.44% in the prior-year period — down 407.1% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting ADAPY's profit margin (-260.82%), review year-over-year change from -51.44%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.